LOADING

Type to search

LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE) – BioSpace

Tags:
Previous Article
Next Article

You Might also Like

Eczema Expo 2024: A Treat for All - National Eczema Association
Phase 3: Delgocitinib improves chronic hand eczema in adolescents – Contemporary Pediatrics
eczemarelief February 5, 2025
Apex Dermatology physician assistant appointed to the American Academy of Physician Associates House of Delegates - The Morning Journal
FDA Expands Label for Abrocitinib to Include Adolescents With … – MD Magazine
eczemarelief February 10, 2023
Dupilumab Promising Long Term for Atopic Dermatitis in Adolescents
Dupilumab Promising Long Term for Atopic Dermatitis in Adolescents
eczemarelief July 11, 2022

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Stories

Eczema Expo 2024: A Treat for All - National Eczema Association
Phase 3: Delgocitinib improves chronic hand eczema in adolescents – Contemporary Pediatrics
Apex Dermatology physician assistant appointed to the American Academy of Physician Associates House of Delegates - The Morning Journal
FDA Expands Label for Abrocitinib to Include Adolescents With … – MD Magazine
Dupilumab Promising Long Term for Atopic Dermatitis in Adolescents
Dupilumab Promising Long Term for Atopic Dermatitis in Adolescents

Next Up

Oxford dermatologist urges people with eczema to seek professional help – This Is Oxfordshire
eczemarelief September 21, 2025
Eczema-Relief.com ©All rights reserved.